'Tremendous' animal data inspire GV, ARCH's $63M booster for Sekar Kathiresan's drive to relegate coronary heart disease to history

In the year since Sekar Kathiresan drew the curtain on Verve Therapeutics and its goal to end the chronic care approach to coronary heart …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'Tremen­dous' an­i­mal da­ta in­spire GV, ARCH's $63M boost­er for Sekar Kathire­san's dri­ve to rel­e­gate coro­nary heart dis­ease to his­to­ry